The first tumor-agonistic approval of a HER2-directed therapy and ADC by FDA was based on the results from the subgroup of patients with HER2-positive Immunohistochemistry 3 + tumors in Destiny-Pantumor02, Destiny-Lung01, and Destiny-CRC01 phase II trials. This evidence concerns the gene ERBB2 and neoplasm.